Antiplatelet therapy after percutaneous coronary intervention.

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Antiplatelet therapy is crucial for preventing thrombotic complications post-percutaneous coronary interventions (PCI).
• However, this therapy significantly increases bleeding risks, necessitating careful risk-benefit assessment.
• Advances in stent technology and understanding of bleeding prognoses have driven changes in antiplatelet regimens.

Purpose of the Study:

• To review the current evidence and rationale for antiplatelet treatment strategies following PCI.
• To discuss the evolution of antiplatelet regimens in light of ischaemic and bleeding risk stratification.
• To explore future directions in antiplatelet therapy after PCI.

Main Methods:

• Systematic review of investigations on antiplatelet therapy in PCI patients.
• Analysis of evidence supporting current treatment guidelines.
• Discussion of prognostic implications of ischaemic and bleeding events.

Main Results:

• Numerous studies have focused on stratifying PCI patients by ischaemic and bleeding risks.
• Evidence supports various antithrombotic treatment options recommended by recent guidelines.
• The field has seen substantial evolution in antiplatelet treatment regimens.

Conclusions:

• Optimizing antiplatelet therapy after PCI requires balancing ischaemic prevention with bleeding risk.
• Patient stratification is key to tailoring antithrombotic regimens.
• Ongoing research and technological advancements will continue to shape future antiplatelet strategies.